Item request has been placed!
×
Item request cannot be made.
×
Processing Request
miR‑34c‑5p targets Notch1 and suppresses the metastasis and invasion of cervical cancer.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE
- Publication Information:
Original Publication: Athens, Greece : D. A. Spandidos
- Subject Terms:
- Abstract:
Micro (mi)RNAs are crucial participants in the progression of cervical cancer (CC). Growing evidence indicates that miRNA (miR)‑34c‑5p is a pivotal tumor suppressor in numerous types of cancer and its functions in CC require further investigating. The present study demonstrated that there was a decreased level of miR‑34c‑5p in CC‑associated cell lines compared with healthy control samples. It also demonstrated that miR‑34c‑5p targeted Notch1 and suppressed CC progression. Dual‑luciferase reporter assays verified the targeted relationship of miR‑34c‑5p and Notch1. The expression of Notch1 in HeLa cells was markedly reduced following miR‑34c‑5p overexpression and the proliferation, migration and invasion of HeLa cells were reduced although apoptosis was accelerated. However, overexpression of miR‑34c‑5p was reversed following the addition of Notch1, which supported the finding of the targeted relationship between miR‑34c‑5p and Notch1. Flow cytometry demonstrated that miR‑34c‑5p inhibited the proliferation of HeLa cells while accelerating apoptosis. The present study concluded that miR‑34c‑5p was a tumor suppressor in CC and may be a novel measure for the future treatment of CC.
- References:
Artif Cells Nanomed Biotechnol. 2018;46(sup2):1120-1126. (PMID: 29916735)
Leukemia. 2018 May;32(5):1180-1188. (PMID: 29479064)
Cancer Res. 2019 Jul 15;79(14):3608-3621. (PMID: 31118200)
Development. 2016 Jun 15;143(12):2160-71. (PMID: 27122169)
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1472-5. (PMID: 25338610)
Sci Rep. 2015 Aug 12;5:13098. (PMID: 26267843)
Exp Ther Med. 2020 Mar;19(3):2059-2066. (PMID: 32104266)
Cancer Chemother Pharmacol. 2013 May;71(5):1159-71. (PMID: 23423488)
Int J Mol Sci. 2015 Jul 02;16(7):14961-78. (PMID: 26147426)
Mol Cancer Res. 2020 May;18(5):787-796. (PMID: 32041737)
Biomed Res Int. 2017;2017:3921258. (PMID: 29082244)
Transl Oncol. 2020 Mar;13(3):100741. (PMID: 32092673)
Cell Death Differ. 2017 Jun;24(6):984-996. (PMID: 28475172)
Int J Mol Sci. 2020 Aug 08;21(16):. (PMID: 32784481)
Onco Targets Ther. 2019 Jan 23;12:759-771. (PMID: 30774364)
Cancers (Basel). 2019 Nov 19;11(11):. (PMID: 31752447)
J Cell Biochem. 2018 Dec;119(12):10278-10290. (PMID: 30129088)
PLoS One. 2018 Nov 9;13(11):e0206948. (PMID: 30412601)
Sci Rep. 2014 Nov 17;4:7072. (PMID: 25400232)
Oncotarget. 2017 Jul 11;8(28):45837-45847. (PMID: 28507277)
Med Sci Monit. 2018 Oct 30;24:7750-7758. (PMID: 30374014)
J Int Med Res. 2020 Mar;48(3):300060520904847. (PMID: 32228202)
Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):936-942. (PMID: 29509241)
Nat Cell Biol. 2016 Apr;18(4):368-9. (PMID: 27027488)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Aging (Albany NY). 2020 Feb 6;12(3):2595-2609. (PMID: 32028262)
Cell Death Dis. 2017 May 25;8(5):e2829. (PMID: 28542138)
Biomed Pharmacother. 2017 Aug;92:586-594. (PMID: 28577497)
Oncol Lett. 2013 Nov;6(5):1447-1452. (PMID: 24179539)
Cell Biochem Biophys. 2020 Jun;78(2):217-225. (PMID: 32152961)
Life Sci. 2018 Apr 15;199:167-178. (PMID: 29452167)
Asian Pac J Cancer Prev. 2013;14(10):5915-20. (PMID: 24289600)
Kaohsiung J Med Sci. 2020 Jul;36(7):501-507. (PMID: 32196955)
- Accession Number:
0 (MIRN34 microRNA, human)
0 (MicroRNAs)
0 (NOTCH1 protein, human)
0 (Neoplasm Proteins)
0 (RNA, Neoplasm)
0 (Receptor, Notch1)
- Publication Date:
Date Created: 20201210 Date Completed: 20210504 Latest Revision: 20210504
- Publication Date:
20231215
- Accession Number:
PMC7751466
- Accession Number:
10.3892/mmr.2020.11759
- Accession Number:
33300051
No Comments.